Back to News
Market Impact: 0.3
1ST Biotherapeutics, SK Biopharma Sign Up To $314.8M Deal For Parkinson's Drug 1ST-104
Source: Nasdaq
Healthcare & BiotechPrivate Markets & VentureProduct Launches
1ST Biotherapeutic and SK Biopharmaceuticals announced an exclusive global licensing agreement and strategic equity-investment partnership to advance 1ST-104, an investigational oral small-molecule treatment for Parkinson's disease. The partnership provides validation and financing support for the clinical candidate, though financial terms and development milestones were not disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
More News
- Crusoe raises $3.9B to build massive data centers and small modular “AI factories”
- Waymo to launch robotaxis in Singapore, its first Southeast Asia market, by 2028
- Waymo to bring autonomous ride-hailing to Singapore in 2028
- Waymo says Singapore will be its next international robotaxi city
- Halozyme prices $1.3 billion convertible notes offering
- Jana Partners pushes Cooper to replace CEO, weigh asset sales- WSJ